Table 3.
Histology, HPV infection, menopausal status, oral contraceptive use, and age for diagnostic and screening populations in Houston, TX and Vancouver, BC
| Diagnostic Population | Screening Population | |
|---|---|---|
| Worst Histology | N=735 | N=707 |
| Negative for Dysplasia | 219 (29.8%) | 489 (69.2%) |
| Atypia | 135 (18.4%) | 129 (18.2%) |
| HPV Associated Changes | 88 (12.0%) | 59 (8.3%) |
| CIN I (Mild Dysplasia | 92 (12.5%) | 18 (2.5%) |
| CIN II (Moderate Dysplasia) | 89 (12.1%) | 7 (1.0%) |
| CIN III (Severe Dysplasia) | 70 (9.5%) | 5 (0.7%) |
| CIS | 41 (5.6%) | 0 (0.0%) |
| Cancer | 1 (0.1%) | 0 (0.0%) |
| Hybrid Capture II | ||
| Negative | 371 (50.5%) | 615 (87.0%) |
| Low-risk | 22 (3.0%) | 16 (2.3%) |
| High-risk | 284 (38.6%) | 59 (8.3%) |
| Both | 54 (7.3%) | 11 (1.6%) |
| Unascertainable | 4 (0.5%) | 6 (0.8%) |
| Menopausal Status | ||
| Premenopausal | 615 (83.7%) | 384 (54.3%) |
| Peri-menopausal | 21 (2.9%) | 93 (13.2%) |
| Postmenopausal | 99 (13.5%) | 230 (32.5%) |
| Oral Contraceptive Use | ||
| No | 260 (35.4%) | 125 (17.7%) |
| Yes | 475 (64.6%) | 582 (82.3%) |
| Age | ||
| Mean ± Std Dev (Yrs) | 36.6 ± 11.7 | 44.9 ± 12.0 |
| Range (Yrs) | 18–85 | 18–80 |
Note: Table includes only those patients included in the analysis, i.e., with useable spectroscopy and biopsies and who passed all quality control measures.